CCI Investigates Roche on Monopoly Charges

April 27, 2017

Anti-trust regulator Competition Commission of India (CCI) has reportedly ordered an investigation against Roche for allegedly using its market position to maintain a monopoly on its breast cancer drug Trastuzumab, according to an article in The Economic Times.

The probe comes in response to a complaint filed by Bengaluru-based Biocon and U.S.-based Mylan, who sell biosimilars of the drug in over a dozen countries, priced at about 25 percent lower than Roche's, the story said. The complaint was filed last year, and the two companies alleged that Roche wrote to doctors, hospitals and regulators in an effort to mislead them about the safety and efficacy of biosimilars.

Read the full story